Lercanidipine
Authoritative Clinical Reference
Navigation
DRUG NAME: Lercanidipine
Therapeutic Class: Antihypertensive
Subclass: Calcium Channel Blocker (CCB) — Dihydropyridine
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
-
Film-coated Tablets: 10 mg, 20 mg
ADULT INDICATIONS + DOSING
Primary Indications (Approved / Standard in India)
1. Essential Hypertension (Mild to Moderate)
| Parameter | Detail |
|
Starting dose
|
10 mg once daily |
|
Titration
|
If blood pressure target is not achieved after a minimum of 2 weeks, increase to 20 mg once daily |
|
Usual maintenance dose
|
10–20 mg once daily |
|
Maximum dose
|
20 mg once daily |
|
Key clinical notes
|
• Administer at least 15 minutes before a meal at the same time each day, preferably in the morning; food taken simultaneously can increase bioavailability by up to 4-fold, leading to unpredictable drug levels — hence the pre-meal recommendation ensures consistent absorption
• Avoid grapefruit or grapefruit juice during therapy (CYP3A4 inhibition increases lercanidipine exposure)
• Lercanidipine is a third-generation dihydropyridine CCB with high lipophilicity and high vascular selectivity; it partitions into cell membranes and produces a gradual onset and prolonged duration of action (true 24-hour coverage with once-daily dosing)
• Compared to amlodipine, lercanidipine causes significantly less ankle oedema — this is attributed to its more balanced effect on precapillary arteriolar and postcapillary venular tone, reducing transcapillary hydrostatic pressure gradient
• Reflex tachycardia is minimal due to gradual onset of vasodilation
• May be used as monotherapy or combined with ACE inhibitors, ARBs, beta-blockers, or thiazide diuretics for enhanced blood pressure control
• No abrupt withdrawal effect; however, gradual dose reduction is prudent in patients on high doses
• Lercanidipine is metabolised extensively by hepatic CYP3A4 — significant interactions with strong CYP3A4 inhibitors and inducers must be anticipated
• Not the first-choice CCB in Indian practice (amlodipine remains the most widely prescribed); however, lercanidipine is preferred when amlodipine-related peripheral oedema limits adherence
• Alcohol should be avoided as it potentiates the vasodilatory and hypotensive effects
|
Secondary Indications — Adults Only (Off-label, if any)
Not applicable. No well-documented off-label indications in Indian clinical practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
NOT AVAILABLE in India for paediatric use. Safety and efficacy of lercanidipine have not been established in children and adolescents below 18 years of age.
Secondary Indications — Paediatric Doses (Off-label, if any)
NOT AVAILABLE in India. No published paediatric dosing data or Indian specialist practice supporting use in this population. Amlodipine is the preferred dihydropyridine CCB for paediatric hypertension.
RENAL ADJUSTMENT
| eGFR (mL/min/1.73 m²) | Recommendation |
|
≥ 30
|
No dose adjustment required; standard dosing applies |
|
< 30 (including dialysis patients)
|
Use with caution; initiate at 10 mg daily and do not increase to 20 mg unless under specialist supervision; monitor blood pressure closely for excessive hypotension |
Note: Lercanidipine is extensively metabolised hepatically with negligible renal excretion of unchanged drug. However, in severe renal impairment, altered protein binding and volume of distribution may increase free drug levels and pharmacological effect. Lercanidipine is not removed by haemodialysis (high protein binding >98%, high lipophilicity).
HEPATIC ADJUSTMENT
| Child-Pugh Class | Recommendation |
|
A (Mild)
|
No dose adjustment required; standard starting dose of 10 mg once daily |
|
B (Moderate)
|
Use with caution; start at 10 mg once daily; avoid uptitration to 20 mg unless clinically essential and under close monitoring; hepatic CYP3A4 metabolism is impaired, leading to increased drug exposure |
|
C (Severe)
|
Avoid use; significantly increased bioavailability and drug exposure expected; no safety data available |
CONTRAINDICATIONS
- Hypersensitivity to lercanidipine, any other dihydropyridine CCB, or any excipient of the formulation
- Untreated congestive heart failure (NYHA III–IV)
- Unstable angina pectoris
- Within 1 month of an acute myocardial infarction
- Severe aortic stenosis
- Left ventricular outflow tract obstruction (e.g., hypertrophic obstructive cardiomyopathy)
- Severe hepatic impairment (Child-Pugh C)
- Concomitant use with strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, telithromycin)
- Concomitant use with ciclosporin (mutual elevation of plasma levels)
- Pregnancy and lactation
CAUTIONS
- Left ventricular dysfunction with reduced ejection fraction (mild to moderate — NYHA I–II; use only with careful monitoring)
- Sick sinus syndrome (if pacemaker not in situ)
- Patients with pre-existing significant hypotension (systolic BP < 90 mmHg)
- Volume- or salt-depleted patients (risk of excessive hypotension on initiation)
- Mild to moderate hepatic impairment (increased drug exposure due to CYP3A4 reliance)
- Severe renal impairment (eGFR < 30 mL/min/1.73 m²)
- Elderly patients (heightened sensitivity to vasodilatory hypotension)
- Concomitant use with moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem, verapamil)
- Concomitant use with CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital) — may reduce lercanidipine efficacy significantly
- Concomitant alcohol use (additive hypotension)
- Patients prone to reflex tachycardia (though risk is lower with lercanidipine than with first-generation dihydropyridines)
- Concomitant digoxin use — monitor for increased digoxin toxicity risk
PREGNANCY
| Parameter | Detail |
|
Overall safety
|
Contraindicated; animal studies have shown reproductive toxicity; no adequate human data available |
|
Preferred alternatives in Indian obstetric practice
|
Methyldopa (first line); labetalol; nifedipine extended-release (the only dihydropyridine CCB with established safety in pregnancy) |
|
When it may be used
|
Should not be used during pregnancy at any stage |
|
Monitoring if inadvertently exposed
|
Monitor maternal blood pressure, fetal growth, and fetal well-being; switch to a safer alternative immediately upon confirmation of pregnancy |
LACTATION
| Parameter | Detail |
|
Compatibility with breastfeeding
|
Not recommended; it is unknown whether lercanidipine is excreted in human breast milk (high lipophilicity suggests probable excretion) |
|
Expected drug levels in milk
|
Unknown; likely low to moderate based on physicochemical properties |
|
Preferred alternatives
|
Nifedipine extended-release (established lactation safety data), labetalol, or amlodipine (limited but reassuring data) |
|
Monitoring in infant
|
If exposure occurs, observe infant for hypotension (lethargy, poor feeding, excessive sleepiness) and poor weight gain |
ELDERLY
- Recommended starting dose: 10 mg once daily
- Titration: Slower titration is advised; assess blood pressure response over 2–4 weeks before considering increase to 20 mg; pharmacokinetic studies show no age-specific dose adjustment is required, but pharmacodynamic sensitivity is increased
- Extra risks: Greater susceptibility to symptomatic hypotension (dizziness, light-headedness), postural hypotension, and falls; age-related decline in hepatic CYP3A4 activity may increase drug exposure; concomitant polypharmacy increases drug interaction risk; monitor renal function as a surrogate for overall cardiovascular reserve
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Effect / Mechanism | Action |
|
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin)
|
Marked increase in lercanidipine plasma levels → excessive hypotension and toxicity; lercanidipine is almost entirely metabolised by CYP3A4 |
Contraindicated — avoid concurrent use
|
|
Ciclosporin
|
Mutual elevation of plasma concentrations of both drugs (lercanidipine increases ciclosporin AUC, ciclosporin inhibits CYP3A4 and P-gp) |
Contraindicated — avoid concurrent use
|
|
Grapefruit juice
|
Inhibition of intestinal CYP3A4 → increased lercanidipine bioavailability by up to 3-fold |
Avoid grapefruit or grapefruit juice during therapy
|
|
CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St John’s Wort)
|
Markedly reduced lercanidipine plasma levels → potential loss of antihypertensive efficacy |
Avoid combination; if unavoidable, blood pressure monitoring is essential and alternative antihypertensive may be needed
|
|
Verapamil / Diltiazem (non-dihydropyridine CCBs)
|
Additive negative inotropic effect and vasodilation; diltiazem also inhibits CYP3A4 increasing lercanidipine levels |
Avoid concurrent use
|
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Action |
|
Beta-blockers (metoprolol, atenolol, bisoprolol)
|
Additive antihypertensive effect; combination is therapeutically rational but may increase risk of hypotension or bradycardia | Monitor blood pressure and heart rate; generally well tolerated in combination |
|
Moderate CYP3A4 inhibitors (fluconazole, erythromycin, verapamil — see also Major section)
|
Moderate increase in lercanidipine exposure | Monitor for excessive hypotension; consider using 10 mg dose without uptitration |
|
Digoxin
|
Lercanidipine may increase digoxin levels | Monitor serum digoxin levels; watch for signs of digoxin toxicity (nausea, visual disturbances, arrhythmias) |
|
Cimetidine (≤ 800 mg/day)
|
Modest increase in lercanidipine bioavailability | Monitor blood pressure; usually clinically insignificant at standard cimetidine doses |
|
Simvastatin
|
Co-administration may increase simvastatin exposure when both are metabolised via CYP3A4 | When combined, administer lercanidipine in the morning and simvastatin in the evening to minimise interaction; monitor for statin-related myopathy |
|
Midazolam
|
Lercanidipine may modestly increase oral midazolam absorption | Monitor for excessive sedation if co-administered |
|
ACE inhibitors / ARBs
|
Additive antihypertensive effect; rational combination therapy for hypertension | Monitor blood pressure; no pharmacokinetic interaction; FDC with enalapril available in some markets |
|
Alcohol
|
Potentiates vasodilatory hypotension | Advise limiting alcohol intake during therapy |
|
Anti-TB drugs (rifampicin — see also Major section; isoniazid — CYP inhibitor)
|
Rifampicin is a strong CYP3A4 inducer (see Major); isoniazid may modestly inhibit CYP enzymes | If on rifampicin-based ATT, consider an alternative antihypertensive such as amlodipine (less CYP3A4 dependent) or a non-CCB class |
COMMON ADVERSE EFFECTS
- Peripheral oedema (less common than with amlodipine but still reported, especially at 20 mg)
- Headache
- Dizziness / light-headedness
- Flushing
- Palpitations
- Fatigue
- Nausea
SERIOUS ADVERSE EFFECTS
- Severe hypotension / syncope: Particularly in volume-depleted patients or when combined with other vasodilators; may require dose reduction or discontinuation
- Angina exacerbation: Rarely reported, likely due to reflex tachycardia or coronary steal phenomenon in patients with significant coronary artery disease
- Gingival hyperplasia: Rare; reversible upon discontinuation; less frequent than with nifedipine or amlodipine
- Allergic reactions: Rare; urticaria, rash; discontinue if suspected hypersensitivity
- Hepatic transaminase elevation: Very rare; monitor if clinical symptoms of hepatic dysfunction arise
MONITORING REQUIREMENTS
| Timing | Parameters |
|
Baseline (before initiation)
|
Blood pressure (sitting and standing), heart rate, hepatic function (LFTs — given CYP3A4 dependence), renal function (creatinine, eGFR), review concomitant medications for CYP3A4 interactions |
|
After initiation / dose change
|
Blood pressure within 2 weeks; assess for peripheral oedema, dizziness, or symptomatic hypotension |
|
Long-term (stable patients)
|
Blood pressure every 3–6 months; periodic hepatic function if on long-term therapy; assessment for peripheral oedema and gingival hyperplasia; review concomitant medication list for new CYP3A4 interactions at each visit |
BRANDS AVAILABLE IN INDIA
- Lerka (Glenmark)
- Lerdip (Cipla)
- Lercanil (Abbott)
- Lercadip (USV)
- Lernica (Micro Labs)
FDCs available:
- Lercanidipine + Enalapril FDC (e.g., Lerka-E) — available in select Indian markets for combination antihypertensive therapy
(Brand availability may vary by region; verify current market availability before prescribing)
PRICE RANGE (INR)
| Strength | Approximate Price per Tablet (INR) |
| 10 mg | ₹5–8 per tablet |
| 20 mg | ₹9–13 per tablet |
- Not listed on NLEM (National List of Essential Medicines); not NPPA price-controlled
- Amlodipine (NLEM-listed) is significantly cheaper and remains the cost-effective first-choice dihydropyridine CCB
- Government supply: not routinely stocked in government hospital formularies; lercanidipine is primarily prescribed in private practice settings
CLINICAL PEARLS
- Key advantage over amlodipine — less peripheral oedema. In patients who develop dose-limiting ankle swelling on amlodipine, switching to lercanidipine often resolves the oedema while maintaining blood pressure control. This is the most common clinical reason for choosing lercanidipine in Indian practice.
- Timing matters — administer before meals. Unlike most antihypertensives, lercanidipine absorption is significantly affected by food. Instruct that the tablet must be taken at least 15 minutes before a meal for consistent bioavailability. Taking it with or after a high-fat meal can increase levels unpredictably.
- CYP3A4 dependence is clinically critical. Before prescribing, always screen concomitant medications for CYP3A4 interactions. Patients on anti-TB therapy with rifampicin will have subtherapeutic lercanidipine levels — switch to an alternative antihypertensive. Patients on azole antifungals or protease inhibitors should not receive lercanidipine.
- Not appropriate for acute blood pressure lowering. Due to its slow onset of action (gradual membrane partitioning), lercanidipine is unsuitable for hypertensive urgencies or emergencies. Use immediate-release nifedipine (with caution) or IV agents for acute BP reduction.
- Renal protective profile. Small studies suggest lercanidipine may preferentially dilate the efferent arteriole (unlike most dihydropyridine CCBs which primarily dilate the afferent arteriole), potentially offering renal haemodynamic benefits in hypertensive patients with proteinuria. However, this is not sufficiently established to be a primary indication.
- Cost consideration. Lercanidipine is more expensive than amlodipine (NLEM-listed) on a per-tablet basis. Reserve it for patients with genuine amlodipine intolerance rather than using it as a first-line agent.
VERSION
RxIndia v0.2 — 01 Mar 2026
REFERENCES
- CDSCO (Central Drugs Standard Control Organisation) — product approval and prescribing information
- Indian Pharmacopoeia
- API Textbook of Medicine — Hypertension management chapter
- AIIMS Treatment Guidelines — Cardiology protocols
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics — Calcium channel blocker pharmacology
- Harrison’s Principles of Internal Medicine — Hypertension management
- NLEM 2022 (for confirmation of non-inclusion of lercanidipine; amlodipine is listed)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.